


ARC 2300N2  
Response to Restriction Requirement



1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail under 37 CFR §1.8 in an envelope addressed to: Honorable Commissioner for Patents and Trademarks, Washington, D.C. 20231.

Date:

March 27, 2003

By:

Yolanda F. Kepner  
Yolanda F. Kepner

#6/B  
RECEIVED  
APR 8 2003  
TECH CENTER 12012900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sonya Merrill et al  
Serial No.: 09/905,526  
Filed: July 13, 2001  
For: HYDROMORPHONE  
THERAPY

Group Art Unit: 1617

Examiner: SHARAREH, S.J.

**Amendment in Response to  
Restriction Requirement  
Under 35 U.S.C § 121**

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

**AMENDMENT**

Sir/Madam:

This correspondence is in response to the Office Action mailed October 17, 2002, regarding the above-entitled application for which the time to respond is through April 17, 2003 upon acceptance of Applicants' petition for extension of time. This amendment is in presented in response to Restriction Requirement contained therein. Reconsideration of this application is requested.

Please amend the application as follows.

**IN THE SPECIFICATION**

On page 1, line 1, in the ~~Title~~, please at the beginning of the lines in the title --  
-ORAL DOSAGE FORMS FOR---- before "HYDROMORPHONE THERAPY," to give  
the new title ----ORAL DOSAGE FORMS FOR HYDROMORPHONE THERAPY ----.